<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00658580</url>
  </required_header>
  <id_info>
    <org_study_id>ELCWP 01994</org_study_id>
    <nct_id>NCT00658580</nct_id>
  </id_info>
  <brief_title>Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer</brief_title>
  <official_title>A Phase III Randomized Study Comparing A Chemotherapy With Cisplatin And Etoposide To A Etoposide Regimen Without Cisplatin For Patients With Extensive Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Lung Cancer Working Party</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Lung Cancer Working Party</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a cisplatin-etoposide regimen improves survival
      in comparison to a regimen containing etoposide and without platinum derivative.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Survival will be dated from the day of randomisation until death or last follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 3 cycles of chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>After every cycle of chemotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">361</enrollment>
  <condition>Small Cell Lung Carcinoma, Extensive Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Every 3 weeks intravenous cisplatin plus etoposide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 3 weeks intravenous epirubicin plus ifosfamide plus etoposide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin + etoposide</intervention_name>
    <description>Cisplatin 90 mg/m² day 1, every 3 weeks
Etoposide 100 mg/m² days 1-3, every 3 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin + ifosfamide + etoposide</intervention_name>
    <description>Epirubicin 60 mg/m² day 1, every 3 weeks
Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks
Etoposide 100 mg/m² days 1-3, every 3 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of small-cell lung cancer

          -  Extensive disease (i.e. a disease with distant metastases or that cannot be included
             in a single irradiation field incorporating primary tumour, mediastinum and
             supraclavicular lymph node(s))

          -  Availability for participating in the detailed follow-up of the protocol

          -  Presence of an evaluable or measurable lesion

          -  Informed consent

        Exclusion Criteria:

          -  Prior treatment with chemotherapy, radiotherapy or surgery

          -  Performance status &lt; 60 on the Karnofsky scale

          -  A history of prior malignant tumor, except non-melanoma skin cancer or in situ
             carcinoma of the cervix or a cured cancer (defined as a disease-free interval &gt; 5
             years)

          -  White blood cells &lt; 4000/mm3

          -  Platelets &lt; 100000/mm3

          -  Serum bilirubin &gt; 1.5 mg/100 ml

          -  Serum creatinine &gt; 1.3 mg/100 ml and creatinine clearance &lt;60 ml/min

          -  Recent myocardial infarction (less than 3 months prior to date of diagnosis)

          -  Congestive cardiac failure or cardiac arrhythmia uncontrolled by medical treatment

          -  Uncontrolled infectious disease

          -  Serious medical or psychological factors which may prevent adherence to the treatment
             schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul Sculier, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>European Lung Cancer Working Party</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hellenic Cancer Institute - St Savas Oncology Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Hospital de Sagunto</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Greece</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.e-cancer.fr</url>
    <description>Trials registry of the French National Cancer Institute</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2008</study_first_submitted>
  <study_first_submitted_qc>April 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2008</study_first_posted>
  <last_update_submitted>February 11, 2015</last_update_submitted>
  <last_update_submitted_qc>February 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Small cell lung carcinoma</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Phase III randomised study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

